Effect of a group-based acceptance and commitment therapy intervention on cognitive emotion regulation and psychological flexibility in patients with bipolar disorder.

Psychol PsychotherApr 11, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Jun-Yan Shi, Long Na, Yan-Hong Du et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed whether group-based acceptance and commitment therapy (ACT) added to treatment as usual (TAU) improved cognitive emotion regulation (CER) and psychological flexibility (PF) in 55 Chinese inpatients with bipolar I or II disorder. Twenty-eight participants received ACT plus TAU in 10 group sessions, and 27 received TAU alone. At the 5-week post-treatment assessment, the ACT-plus-TAU group showed greater improvements in CER and PF, as well as residual mania and depressive symptoms, than the TAU group. The abstract reports no numerical effect estimates.

Key findings

  • At 5 weeks, CER improved more with ACT plus TAU than with TAU alone.
  • The ACT-plus-TAU group showed greater improvement in PF than the TAU group.
  • Residual mania and depressive symptoms improved more in the ACT-plus-TAU group.

Why it matters

The findings suggest that a structured group ACT intervention may address emotion regulation and psychological flexibility alongside residual mood symptoms in people receiving care for bipolar disorder. These processes may be relevant treatment targets, although the abstract provides no effect estimates to indicate the magnitude of benefit.

What to keep in mind

The study involved 55 inpatients at one tertiary psychiatric hospital in China, and outcomes were assessed only at baseline and 5 weeks; longer-term effects are not reported.

Source

Published in Psychol Psychother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.